Tumors were grouped into molecular subtypes based on the expression of ER, PR and HER2 (see Supplemental Fig. 1 for breakdown of all breast cancer TMAs, tissue sections, associated clinical data, corresponding experiments used, and molecular subtype grouping). This evidence concerns the gene ERBB2 and breast carcinoma.